What is it?
What bromantane is
1Bromantane is a synthetic adamantane derivative sold or discussed under the name Ladasten in Russian clinical literature. It is not a botanical or nutrient; the evidence base is closer to a research and drug-development compound than a typical dietary supplement ingredient.
Evidence snapshot
3The best human evidence is short-term and population-specific: Russian-language studies evaluated Ladasten in people with asthenic or A nervous-exhaustion term used for physical and mental fatigue.Source symptom profiles. Those data can inform fatigue-related mental-energy claims, but they should not be stretched into broad claims for healthy cognition, neuroprotection, or athletic performance.
Names, aliases and forms
Mechanisms of action
Dopaminergic and catecholamine pathways
5Animal work suggests ladasten can influence dopamine-related pathways, including tyrosine hydroxylase expression and dopamine/L-DOPA measures in brain regions studied in rats. This supports a plausible stimulant-like mechanism, but it does not prove the same magnitude or outcome in humans.
Synaptic plasticity signal
5In rat hippocampal preparations, ladasten affected short-term and long-term potentiation markers through protein-synthesis and dopamine-dependent mechanisms. This is mechanistic context only, not proof that bromantane improves memory or learning in people.
Potential effects and evidence map
Human evidence centers on Russian-language clinical studies in asthenic or neurasthenic populations, including a placebo-controlled study and a multicenter 28-day study at 50-100 mg/day. Evidence is not strong enough to generalize to healthy cognitive enhancement, and many mechanism claims come from animal or in vitro work.
May support fatigue-related mental energy in the asthenic/neurasthenic populations studied as Ladasten; this does not establish broad healthy-user cognitive enhancement.
Clinical literature describes anxiolytic-like effects alongside stimulant-like effects in asthenic/neurasthenic populations, but evidence outside those settings is limited.
Has been studied for quality-of-life and wellbeing-related outcomes in short Russian clinical studies, not as a general mood supplement.
Animal and in vitro data suggest effects on dopaminergic neurotransmission and hippocampal synaptic plasticity, but human memory or learning benefits are not established.
Typical dosages and timing
Published Russian clinical literature used Ladasten at a daily dose of 50-100 mg for 28 days. This is a researched context, not a public dosing recommendation.
The multicenter study assessed patients during a 28-day course and again one month after therapy ended.
Dose-response, optimal supplement dosing, timing, long-term cycling, and acute human effect duration have not been established by high-quality public evidence.
Onset, duration and tolerance
The Ladasten instruction reports The time it takes to reach the highest measured blood concentration after a dose.Source of 2-4 hours. This is a blood-concentration measure and was not used as the effect-onset field.
Russian Ladasten product information reports a T1/2 of 11.21 hours; the compact page field rounds this to ~11 hours. Treat this as label-context pharmacokinetics rather than an effect-duration estimate.
Urinary metabolite detection can matter for doping-control context, but it was not used here as an estimate of acute effect duration.
The day-3 onset signal comes from a short clinical study in asthenic disorders. Tmax is a pharmacokinetic peak, not a proven subjective onset. Human acute effect duration remains unestablished from the sources used here.
Safety, side effects and risk profile
Stimulant-like activity and limited human safety detail justify caution for restlessness, overstimulation, or sleep disruption, especially outside studied dosing contexts.
Animal data reported cardiovascular and sympathetic-adrenal effects; human cardiovascular risk is not well characterized.
Potential interaction risk is plausible with stimulants, dopaminergic agents, and psychiatric or neurologic medicines, but direct human interaction studies are lacking.
Pregnancy and lactation use should be treated as high-caution because animal reproductive/development findings exist and human safety data are absent.
One 28-day placebo-controlled clinical study looked for withdrawal syndrome and reported none, but long-term and non-clinical use remain uncertain.
Bromantan/Bromantane is an anti-doping concern for competitive athletes and local supplement or medicine status must be checked by jurisdiction.
Human evidence is short-term, mostly Russian-language, and focused on asthenic/neurasthenic populations; healthy-user efficacy and long-term safety are not established.
The 728-patient multicenter analysis reported adverse effects in 3% of patients, treatment discontinuation in 0.8%, and no serious adverse effects. This should be interpreted as short-term clinical context, not a full consumer safety profile.
Rat toxicology work reported stimulation at lower experimental doses and suppressed activity, autonomic signs, and gastrointestinal effects at much higher doses. Animal dose levels do not translate directly to human dosing.
Animal reproductive/development research reported changes in litter size, survival, and development measures after bromantan exposure. Human pregnancy and lactation safety data are not established.
Interactions and cautions
Because animal studies indicate dopaminergic and catecholamine-related effects, combining bromantane with stimulants, dopaminergic agents, or other activating compounds should be treated as an unreviewed risk.
Direct human interaction studies are lacking. People using medicines that affect dopamine, norepinephrine, mood, sleep, or seizure threshold need individualized medical review rather than relying on nootropic dosing anecdotes.
Legal and regulatory status
WADA materials list Bromantan/Bromantane as a stimulant anti-doping concern. Competitive athletes should check the current annual list, sport rules, and any therapeutic-use-exemption process before exposure.
This profile does not assume bromantane is a lawful dietary supplement or approved medicine in every market. Verify country-specific medicine, novel-food, import, labeling, and platform rules before listing, importing, or buying.
Practical buying and quality notes
- Prefer products with recent batch-specific identity and purity testing from an independent lab. Bromantane products without a credible COA should be treated as high uncertainty.
- Be skeptical of disease, guaranteed dopamine, guaranteed motivation, or broad cognitive-enhancement claims. The human evidence used here is narrower than those marketing claims.
- Athletes should treat product listings that describe bromantane as a nootropic or supplement as still relevant to anti-doping rules.9
FAQ
What is bromantane?
1Bromantane is a synthetic adamantane derivative also discussed as Ladasten. It has been studied mainly in Russian clinical literature, not as a mainstream nutrient or botanical supplement.
Is bromantane proven for healthy cognitive enhancement?
3No. The best human evidence is short-term and focused on asthenic/neurasthenic clinical populations. Mechanistic animal data should not be treated as proof of healthy-user cognitive benefits.
What bromantane dosage has been studied?
2Published Russian Ladasten clinical literature used 50-100 mg/day for 28 days. That studied range is not a public dosing recommendation and does not establish long-term consumer use.
Is bromantane allowed for athletes?
9Bromantan/Bromantane is an anti-doping concern under WADA stimulant rules. Athletes should check the current list and sport-specific rules before use or exposure.
Is bromantane safe?
2Short-term clinical literature reported low overall adverse effects in one multicenter study, but long-term safety, interactions, pregnancy/lactation safety, and grey-market product quality remain uncertain.
References
- PubChem Compound Summary for CID 4660557, Bromantane. National Center for Biotechnology Information.
- Voznesenskaia TG, Fokina NM, Iakhno NN. Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(5 Pt 1):17-26. PMID: 21322821.
- Neznamov GG, Siuniakov SA, Teleshova SE, et al. Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia: results of the comparative clinical study with placebo. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(5):20-26. PMID: 19491814.
- Siuniakov SA, Grishin SA, Teleshova ES, Neznamov GG, Seredenin SB. Pilot clinical trial of ladasten. Eksp Klin Farmakol. 2006;69(4):10-15. PMID: 16995430.
- Mikhaylova M, Vakhitova JV, Yamidanov RS, Salimgareeva MKh, Seredenin SB, Behnisch T. The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats. Neuropharmacology. 2007;53(5):601-608. doi:10.1016/j.neuropharm.2007.07.001. PMID: 17854844.
- Iezhitsa IN, Spasov AA, Bugaeva LI, Morozov IS. Toxic effect of single treatment with bromantane on neurological status of experimental animals. Bull Exp Biol Med. 2002;133(4):380-383. doi:10.1023/a:1016206306875. PMID: 12124651.
- Iezhitsa IN, Spasov AA, Bugaeva LI. Effects of bromantan on offspring maturation and development of reflexes. Neurotoxicol Teratol. 2001;23(2):213-222. doi:10.1016/S0892-0362(01)00119-2. PMID: 11348840.
- Morozov IS, Efimova LP, Kryzhanovskii SA. The effect of bromantane on the cardiovascular and sympathetic-adrenal systems in animals. Eksp Klin Farmakol. 2000;63(1):33-36. PMID: 10763107.
- World Anti-Doping Agency. The Prohibited List.
- Medi.ru. Ladasten (adamantylbromphenylamine) official instructions for use.
- Oliynyk S, Oh S. The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance. Biomolecules & Therapeutics. 2012;20(5):446-456.